{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PSC"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSC\",,,,,undefined,":{"symbol":"PSC","market":"US","secType":"STK","nameCN":"Principal U.S. Small-Cap Multi-Factor ETF","latestPrice":47.4199,"timestamp":1745601548916,"preClose":47.39,"halted":0,"volume":29431,"delay":0,"floatShares":15300001,"shares":15300001,"eps":0.9,"marketStatus":"Trading","change":0.0299,"latestTime":"04-25 13:22:22 EDT","open":47.22,"high":47.4199,"low":46.95,"amount":1388186.898517,"amplitude":0.009916,"askPrice":47.41,"askSize":1000,"bidPrice":47.28,"bidSize":1700,"shortable":3,"etf":1,"ttmEps":0.9,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745611200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":47.39,"sharesOutstanding":15300001,"nav":45.854278,"aum":712356147.09,"dividendRate":0.008352,"bidAskSpread":0.002809,"postHourTrading":{"tag":"盘后","latestPrice":47.49,"preClose":47.39,"latestTime":"16:05 EDT","volume":2,"amount":94.78,"timestamp":1745525113762},"volumeRatio":0.310684},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSC\",,,,,undefined,":{"symbol":"PSC","floatShares":15300001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.310684,"shares":15300001,"dividePrice":0.396028,"high":47.4199,"amplitude":0.009916,"preClose":47.39,"low":46.95,"week52Low":42.36,"pbRate":"--","week52High":57.24,"institutionHeld":0,"latestPrice":47.4199,"committee":0.259259,"eps":0.9,"divideRate":0.008352,"volume":29431,"delay":0,"ttmEps":0.9,"open":47.22,"prevYearClose":51.27,"prevWeekClose":45.92,"prevMonthClose":48.5596,"prevQuarterClose":48.5596,"fiveDayClose":45.92,"twentyDayClose":49.1211,"sixtyDayClose":53.41},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PSC\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSC\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529647669","title":"Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication","url":"https://stock-news.laohu8.com/highlight/detail?id=2529647669","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529647669?lang=en_us&edition=fundamental","pubTime":"2025-04-24 14:14","pubTimestamp":1745475240,"startTime":"0","endTime":"0","summary":"Elafibranor showed a favorable safety profile and demonstrated dose-dependent efficacy over 12 weeks for people living with PSC, a rare liver disease that currently has no approved treatment options. Patients treated with elafibranor versus placebo showed significant improvements in liver biochemical parameters, including alkaline phosphatase . Stabilization of non-invasive markers of liver fibrosis were observed in patients on elafibranor versus placebo. PARIS, FRANCE, 24 April 2025 Ipsen  will be presenting data from the late-breaking abstract on elafibranor in the investigational Phase II ELMWOOD study at the European Association for the Study of the Liver  congress as an oral presentation, on 10 May at 11.15 CET. For the first time data highlighting the potential of elafibranor in treating people living with primary sclerosing cholangitis  will be presented. PSC is a rare liver disease that currently has no approved treatment options.Patients on elafibranor also had stabilization i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/breaking-elafibranor-primary-sclerosing-cholangitis-061400283.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALT","LU1242518857.USD","BK4585","BK4007","LU0053671581.USD","LU1559883803.SGD","LU1242518931.SGD","LU1878469433.USD","EC","BK4183","IPSEY","BK4599","IPSEF","GGT","LU0566484027.USD","BK4139","BK4201","PSC","ELF","PBC","BK4588","LU0979878070.USD"],"gpt_icon":0},{"id":"2529806511","title":"Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2529806511","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529806511?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:00","pubTimestamp":1745236800,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, April 21, 2025  -- Chemomab Therapeutics, Ltd., , a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that clinical data on nebokitug  for the treatment of patients with primary sclerosing cholangitis  will be presented at major upcoming scientific conferences including DDW25, Digestive Disease Week 2025; EASL 2025, the Annual Congress of the European Association for the Study of the Liver; and BSG LIVE'25, the British Society of Gastroenterology’s annual meeting. Chemomab will report information on the content of the presentations after the meeting embargoes lift.Oral presentation: CM-101, a novel monoclonal antibody targeting CCL24, was safe, well-tolerated and showed improvements of biomarkers associated with inflammation, fibrosis and cholestasis in patients with primary sclerosing cholangitis : The Spring Study. Paul Pockros, MD, Director, Liver Disease Scripps Clinic and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chemomab-therapeutics-present-nebokitug-clinical-120000003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PSC","BK4007","CMMB","LENZ"],"gpt_icon":0},{"id":"2527490299","title":"Chemomab Announces New Medical and Clinical Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2527490299","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527490299?lang=en_us&edition=fundamental","pubTime":"2025-04-15 20:00","pubTimestamp":1744718400,"startTime":"0","endTime":"0","summary":"David M. Weiner, MD, Rejoins Chemomab as Interim Chief Medical Officer, Bringing Extensive Biotechnology and Pharmaceutical Industry R&D, Drug Development and Strategic Experience. Jack Lawler, Who Oversaw the Conduct of Chemomab’s Successful Phase 2 SPRING Trial inPSC, Assumes Chief Development Officer Role. Dr. Weiner commented, “I welcome the opportunity to rejoin Chemomab at this exciting time for the company. We have reported compelling clinical proof-of-concept data showing that nebokitug has the potential to become the first FDA-approved drug for PSC with disease-modifying activity and that it also may have potential in other fibro-inflammatory diseases. These are challenging times for o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chemomab-announces-medical-clinical-appointments-120000196.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CMMB","BK4139","PSC"],"gpt_icon":0},{"id":"2527216355","title":"Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2527216355","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527216355?lang=en_us&edition=fundamental","pubTime":"2025-04-14 20:30","pubTimestamp":1744633800,"startTime":"0","endTime":"0","summary":"LIVMARLI Tablet formulation approved for patients with Alagille Syndrome  and Progressive Familial Intrahepatic Cholestasis . FOSTER CITY, Calif., April 14, 2025----Mirum Pharmaceuticals, Inc.  today announced that the U.S. Food and Drug Administration  has approved a new tablet formulation of LIVMARLI  for the treatment of cholestatic pruritus in patients with Alagille syndrome  and Progressive Familial Intrahepatic Cholestasis .\"The approval of LIVMARLI in tablet form provides a meaningful additional treatment option for patients with ALGS and PFIC. It allows flexibility for patients and physicians, with the liquid dosing used by the youngest patients and a convenient one-tablet per dose option for older patients,\" said Peter Radovich, president and chief operating officer at Mirum. \"We have had tremendous success with LIVMARLI since its launch and we hope that the availability of the tablet will provide convenience that positively impacts patients’ lives.\". LIVMARLI tablets are plan","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mirum-livmarli-now-fda-approved-123000969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4520","FSV","IBAT","BK4505","BK4532","PSC","BSEP","X","BK4006","BK4079","BK4516","MIRM","BK4588","ALGS","BK4139"],"gpt_icon":0}],"pageSize":4,"totalPage":12,"pageCount":1,"totalSize":47,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSC\",params:#limit:5,,,undefined,":[{"date":"2025-04-01","symbol":"PSC","amount":0.110318,"announcedDate":"2025-01-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-01","defaultRemindTime":1743514200000,"name":"Principal U.S. Small-Cap Multi-Factor ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-03","payableDate":"2025-04-01","currency":"USD","dateTimestamp":1743480000000,"payDate":"2025-04-03"},{"date":"2024-12-27","symbol":"PSC","amount":0.07952,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-27","defaultRemindTime":1735309800000,"name":"Principal U.S. Small-Cap Multi-Factor ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-27","currency":"USD","dateTimestamp":1735275600000,"payDate":"2024-12-31"},{"date":"2024-10-01","symbol":"PSC","amount":0.1071,"announcedDate":"2024-09-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-10-01","defaultRemindTime":1727789400000,"name":"Principal U.S. Small-Cap Multi-Factor ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-10-03","payableDate":"2024-10-01","currency":"USD","dateTimestamp":1727755200000,"payDate":"2024-10-03"},{"date":"2024-07-01","symbol":"PSC","amount":0.09909,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-07-01","name":"Principal U.S. Small-Cap Multi-Factor ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-03","payableDate":"2024-07-01","currency":"USD","dateTimestamp":1719806400000,"payDate":"2024-07-03"},{"date":"2024-04-01","symbol":"PSC","amount":0.096411,"announcedDate":"2024-03-28","type":"dividend","market":"US","newRecordDate":"2024-04-02","defaultRemindTime":1711978200000,"name":"Principal U.S. Small-Cap Multi-Factor ETF","recordDate":"2024-04-04","payableDate":"2024-04-02","currency":"USD","dateTimestamp":1711944000000,"payDate":"2024-04-04"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSC\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-28","recordDate":"2016-12-30","paymentDate":"2017-01-04","value":0.0954808,"currency":"USD"},{"executeDate":"2017-04-03","recordDate":"2017-04-05","paymentDate":"2017-04-07","value":0.073752,"currency":"USD"},{"executeDate":"2017-07-03","recordDate":"2017-07-06","paymentDate":"2017-07-10","value":0.078723,"currency":"USD"},{"executeDate":"2017-10-02","recordDate":"2017-10-03","paymentDate":"2017-10-05","value":0.053592,"currency":"USD"},{"executeDate":"2018-04-02","recordDate":"2018-04-03","paymentDate":"2018-04-05","value":0.083439,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSC\",market:\"US\",delay:false,,,undefined,":{}}}